J. Zujewski

2.7k total citations · 1 hit paper
16 papers, 1.9k citations indexed

About

J. Zujewski is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, J. Zujewski has authored 16 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in J. Zujewski's work include HER2/EGFR in Cancer Research (4 papers), Estrogen and related hormone effects (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). J. Zujewski is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Estrogen and related hormone effects (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). J. Zujewski collaborates with scholars based in United States, Malaysia and Belgium. J. Zujewski's co-authors include Mathew J. Ellis, Torsten O. Nielsen, Tracy Lively, Lisa M. McShane, Janine Salter, Seungmok Paik, Christos Sotiriou, Daniel F. Hayes, Ludmila Prudkin and N. Lynn Henry and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. Zujewski

16 papers receiving 1.9k citations

Hit Papers

Assessment of Ki67 in Breast Cancer: Recommendations from... 2011 2026 2016 2021 2011 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
    2011 1.5k citations Torsten O. Nielsen, Roger A’Hern et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Zujewski United States 10 1.1k 1.0k 548 388 290 16 1.9k
Tracy Lively United States 10 991 0.9× 1.2k 1.2× 536 1.0× 411 1.1× 353 1.2× 19 2.1k
MM Regan Switzerland 9 1.0k 0.9× 1.1k 1.1× 329 0.6× 377 1.0× 294 1.0× 32 1.7k
F P O’Malley Canada 16 1.0k 1.0× 911 0.9× 594 1.1× 526 1.4× 278 1.0× 27 2.0k
K. Anderson United States 12 1.4k 1.3× 1.6k 1.6× 1.2k 2.1× 386 1.0× 278 1.0× 20 2.7k
Elizabeth Mallon United Kingdom 19 1.0k 1.0× 1.1k 1.0× 708 1.3× 443 1.1× 337 1.2× 32 2.0k
Lila Zabaglo United Kingdom 16 1.2k 1.1× 1.4k 1.3× 421 0.8× 356 0.9× 399 1.4× 37 1.9k
Kalliopi P. Siziopikou United States 25 1.0k 0.9× 888 0.9× 1.0k 1.9× 426 1.1× 275 0.9× 75 2.3k
Véronique Becette France 18 1.0k 1.0× 983 1.0× 889 1.6× 313 0.8× 412 1.4× 56 2.2k
Ellen C.M. Mommers Netherlands 16 815 0.8× 805 0.8× 700 1.3× 240 0.6× 201 0.7× 19 1.8k
F. Spyratos France 23 1.0k 0.9× 796 0.8× 906 1.7× 290 0.7× 228 0.8× 52 2.0k

Countries citing papers authored by J. Zujewski

Since Specialization
Citations

This map shows the geographic impact of J. Zujewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Zujewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Zujewski more than expected).

Fields of papers citing papers by J. Zujewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Zujewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Zujewski. The network helps show where J. Zujewski may publish in the future.

Co-authorship network of co-authors of J. Zujewski

This figure shows the co-authorship network connecting the top 25 collaborators of J. Zujewski. A scholar is included among the top collaborators of J. Zujewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Zujewski. J. Zujewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hodges-Gallagher, Leslie, David C. Myles, Pamela Klein, et al.. (2020). OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors. European Journal of Cancer. 138. S55–S55. 7 indexed citations
2.
3.
Nielsen, Torsten O., Roger A’Hern, R. Charles Coombes, et al.. (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI Journal of the National Cancer Institute. 103(22). 1656–1664. 1488 indexed citations breakdown →
4.
Kohn, Elise C., Christina M. Annunziata, Lori M. Minasian, et al.. (2011). A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients.. Journal of Clinical Oncology. 29(15_suppl). 5019–5019. 12 indexed citations
5.
Annunziata, Christina M., Lori M. Minasian, J. Zujewski, et al.. (2011). Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).. Journal of Clinical Oncology. 29(15_suppl). 2520–2520. 19 indexed citations
6.
Annunziata, Christina M., Gisele Sarosy, Lori M. Minasian, et al.. (2010). Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). TPS163–TPS163. 2 indexed citations
7.
Perez, EA, MF Press, RB Jenkins, et al.. (2010). Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005). Cancer Research. 70(24_Supplement). PD10–2. 2 indexed citations
8.
Eng‐Wong, Jennifer, Reynolds Jc, David Venzon, et al.. (2009). Effect of exemestane on bone mineral density in postmenopausal women at increased risk for breast cancer.. Cancer Research. 69(2_Supplement). 5086–5086. 1 indexed citations
9.
Zujewski, J., Ivan D. Horak, C.J. Bol, et al.. (2000). Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer. Journal of Clinical Oncology. 18(4). 927–927. 218 indexed citations
10.
Zujewski, J., Lee H. Pai, Lalage M. Wakefield, et al.. (1999). Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Research and Treatment. 57(3). 277–283. 30 indexed citations
11.
Warren, M K, et al.. (1998). Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells. Bone Marrow Transplantation. 22(5). 457–468. 18 indexed citations
12.
Tolcher, Anthony W., Joyce O’Shaughnessy, R B Weiss, et al.. (1997). A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.. PubMed. 3(5). 755–60. 22 indexed citations
13.
14.
Schwartz, Gretchen N., Frances T. Hakim, J. Zujewski, et al.. (1996). Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow. British Journal of Haematology. 92(3). 537–547. 9 indexed citations
15.
16.
Hakim, Fran, et al.. (1996). Development of paroxysmal nocturnal hemoglobinuria after chemotherapy [letter]. Blood. 88(12). 4725–4726. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tracy Lively Breakdown of academic impact, for papers by MM Regan Breakdown of academic impact, for papers by F P O’Malley Breakdown of academic impact, for papers by K. Anderson Breakdown of academic impact, for papers by Elizabeth Mallon Breakdown of academic impact, for papers by Lila Zabaglo Breakdown of academic impact, for papers by Kalliopi P. Siziopikou Breakdown of academic impact, for papers by Véronique Becette Breakdown of academic impact, for papers by Ellen C.M. Mommers Breakdown of academic impact, for papers by F. Spyratos
Rankless by CCL
2026